- Research article
- Open Access
The influence of dietary peptide inhibitors of angiotensin-converting enzyme on the hypotensive effects of enalapril
Journal of Pharmaceutical Health Care and Sciences volume 1, Article number: 17 (2015)
Enalapril is an antihypertensive medicine that inhibits angiotensin I-converting enzyme (ACE). The present study investigated interactions between enalapril and a fermented milk product (FMP) containing the ACE-inhibitory peptides, Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP).
Single-dose and long-term (6-week) in vivo studies were used to investigate the effects of enalapril and FMP on blood pressure in spontaneously hypertensive rats.
Single-dose oral administration of concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg) produced a lower antihypertensive effect than enalapril monotherapy. However, this effect was not observed in animals administered a lower dose of FMP (VPP, IPP: 1.75 mg/kg) along with enalapril. In rats administered enalapril concomitantly with a fish protein product (FPP) containing a different ACE inhibitory peptide (Leu-Lys-Pro-Asn-Met), significant attenuation of the antihypertensive effect was also observed 1 and 2 h after administration, as compared to enalapril monotherapy. During a 6-week oral administration study, the enalapril monotherapy group showed significant antihypertensive effects compared to those observed in the controls on day 28. Oral administration of enalapril and FMP, with a 1-h interval between doses, resulted in significant antihypertensive effects on day 35, indicating a delayed onset in comparison to enalapril monotherapy. In rats receiving enalapril monotherapy for 28 days, followed by 14 days of concomitant FMP, significant antihypertensive effects were observed after day 35, and these did not differ significantly from the effects observed during enalapril monotherapy.
The present findings suggested that long-term concomitant intake of FMP and enalapril could influence the antihypertensive effects of this drug.
Foods for Specified Health Uses (FOSHU) have been approved by the Japanese Ministry of Health, Labour and Welfare after demonstrating tangible benefits. FOSHU may contain biologically active ingredients with a range of activities, such as decreasing blood pressure or cholesterol levels. These provide prophylaxis for lifestyle-related diseases, such as hypertension, diabetes, obesity, osteoporosis, and cardiovascular disease . At present, many FOSHU such as tea, beverages, gum, etc. are available over-the-counter and have been widely adopted in everyday life.
Hypertension can be treated using lifestyle measures, such as increasing physical activity, maintaining a normal body weight, and adopting a healthy diet. In addition, borderline hypertensive subjects can ingest FOSHU containing peptide inhibitors of angiotensin I-converting enzyme (ACE). Several randomized trials and meta-analyses have shown that some peptides derived from milk proteins, such as Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), decrease systolic blood pressure [2–4]. VPP and IPP, first isolated from milk fermented with Lactobacillus helveticus, show ACE-inhibitory activity and their antihypertensive effects have been studied extensively in spontaneously hypertensive rats (SHR) [5, 6], and in humans [7, 8]. At present, a fermented milk product (FMP) containing these peptides is commercially available in Japan (trade name, Ameel S®) and this FOSHU is readily available to people, irrespective of whether they are taking other antihypertensive medications.
There are few published studies on the effects of combined intake of FMP and a prescribed ACE inhibitor. The present study therefore investigated the hypotensive effects of concomitant use of FMP and an ACE inhibitor, enalapril. Because antihypertensive drugs are commonly administered continuously over a long period, this study investigated long-term administration of FMP and enalapril. An initial investigation of concomitant oral administration of enalapril and either FMP or a commercially available fish protein product (FPP; trade name, Peptide Straight®) containing a bioactive peptide (Leu-Lys-Pro-Asn-Met; LKPNM) was carried out . We then conducted a long-term oral administration study to model a situation where patients took concomitant FOSHU and enalapril, and the other scenario where patients already taking oral antihypertensive medication started to take FOSHU. SHR therefore received daily oral concomitant enalapril and FMP for 6 weeks, or enalapril monotherapy for 28 days, followed by concomitant FMP for a further 14 days.
This study was performed in accordance with the guidelines for animal experimentation of Teikyo University. Male SHR rats were purchased from the Sankyo Laboratory Service Corporation (Tokyo, Japan) and then underwent a 4-week preliminary observation at 22-24 °C, 55 % humidity, with 12 h of lighting (0800–2000) and food and water ad libitum. Thirteen-week-old rats (body weight: 250–290 g) were used for the single administration study and 15-week-old rats (body weight: 235–270 g) were used for the long-term administration study.
One Ameel S Handy Tab® (CALPIS Co. Ltd., Tokyo, Japan), labeled as containing 1.7 mg of VPP and IPP in total, was crushed and dissolved in distilled water to give a total volume of either 2.9 mL (for dosing at 3.5 mg/kg ) or 5.8 mL (for dosing at 1.75 mg/kg). In the enalapril monotherapy group, 0.5 mg/mL enalapril maleate (Wako Junyaku Inc., Tokyo, Japan) solution was prepared using distilled water. For concomitant enalapril and FMP administration, 1 Ameel S Handy Tab® was crushed and added to a 1.0 mg/mL enalapril solution to give a total volume of 2.9 mL. In the FPP monotherapy group, one bag containing 1.9 g of Peptide Straight® (Japan Supplement Foods Co. Ltd., Osaka City, Japan; 4.75 mg LKPNM) was crushed and dissolved in distilled water to obtain a total volume of 3.5 mL. In the concomitant FPP and enalapril group, 1.9 g Peptide Straight® was crushed and added to a 0.4 mg/mL enalapril solution to give a total volume of 3.5 mL. The control group was orally administered 6 mL/kg distilled water.
Test product administration
Three types of single administration studies were conducted using the following 4 groups (n = 4 rats per group): Study 1, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy, (III) FMP (VPP, IPP: 3.5 mg/kg), and (IV) concomitant enalapril (3 mg/kg) and FMP (VPP, IPP: 3.5 mg/kg); Study 2, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy, (III) FMP (VPP, IPP: 1.75 mg/kg), and (IV) concomitant enalapril (3 mg/kg) and FMP (VPP, IPP: 1.75 mg/kg); and Study 3, (I) control (distilled water), (II) enalapril (3 mg/kg) monotherapy; (III) FPP (LKPNM; 10 mg/kg LKPNM .), and (IV) concomitant enalapril (3 mg/kg) and FPP (LKPNM; 10 mg/kg LKPNM). These doses of FMP and enalapril were based on the human doses of 5–10 mg enalapril daily and 3.4 mg VPP/IPP in FMP. The test products were administered orally using a nasogastric tube (KN-349, Natsume, Tokyo, Japan) at the scheduled time (1000–1145). In the long-term administration study, rats received each preparation separately, with an interval of 1 h between the first and second administration. This study was conducted using the following groups and dosing schedules (n = 5 rats per group): (I) control (distilled water, followed by distilled water); (II) enalapril monotherapy (distilled water, followed by 3 mg/kg enalapril); (III) concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg), followed by 3 mg/kg enalapril); and (IV) delayed combination (distilled water, followed by 3 mg/kg enalapril for 28 days, switching to FMP [VPP, IPP: 3.5 mg/kg], followed by 3 mg/kg enalapril for a further 14 days). During the 6-week study period, administration took place daily at scheduled times (first administration: 1130–1200; second administration: 1230–1300).
Blood pressure measurement
Systolic blood pressure was measured by the tail cuff method using the Non-Preheating, Non-Invasive Blood Pressure Monitor for Mice and Rats (MK-2000, Muromachi Kikai, Tokyo, Japan). Blood pressure measurements were performed 5–10 times consecutively when the rat was at rest. During the single administration study, blood pressure was measured immediately before administration and at 1, 2, 4, and 6 h after administration. During the long-term administration study, systolic blood pressure was measured immediately before the start of administration and prior to oral dosing on days 3, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, and 42 (after day 42, no test product was administered). This study schedule was based on a previous report .
A change in the hypertensive state was calculated as a percentage of systolic blood pressure measured immediately before the start of administration.
The mean blood pressure value was used for analysis. Values were expressed as the mean ± standard error of the mean (SE). After one-way analysis of variance, the Bonferroni/Dunn or Scheffe multiple comparison test was performed.
Results and discussion
Single administration study
In the initial single oral dose study, blood pressure was measured after administration of a mixture of enalapril and FMP, to evaluate the optimal method of administration for the subsequent long-term study. As a result, compared to the control group, the enalapril monotherapy group showed significant antihypertensive effects from 1 to 6 h after administration. No significant antihypertensive effects was observed in the concomitant enalapril and FMP (VPP, IPP: 3.5 mg/kg) group 1 h after administration, although significant antihypertensive effects were observed at 2 and 4 h (p < 0.05 each). However, significant attenuation of antihypertensive effects was observed at 4 h in the concomitant enalapril and FMP group, compared with the enalapril monotherapy group (p < 0.05; Fig. 1a). The antihypertensive effects of enalapril were not reduced in the concomitant enalapril and FMP (VPP, IPP: 1.75 mg/kg) group (Fig. 1b), which showed significant blood pressure reduction from 1 to 6 h (p < 0.01 and p < 0.05) post administration. Concomitant administration of enalapril and FPP (LKPNM, 10 mg/kg) also produced significant antihypertensive effects 4 and 6 h after administration. However, these were significantly attenuated at 1 and 2 h, as compared with the enalapril monotherapy group (p < 0.05; Fig. 1c). This study indicated that co-administration of FMP or FPP reduced the antihypertensive effects of enalapril. Therefore, these results suggested possible interactions between enalapril and ACE inhibitory peptides from two FOSHU preparations. Because enalapril and FMP/FPP both inhibit ACE activity, they would be expected to have an additive antihypertensive effect. The mechanism underlying the interaction observed in this study may therefore relate to competition for absorption processes in the gut, resulting in reduced enalapril-mediated antihypertensive activity. A previous study has reported that the antihypertensive effects of captopril decreased when this ACE inhibitor was administered concomitantly with the Val-Tyr dipeptide, because of their competition for peptide transporter 1 during intestinal absorption . Similarly, the intestinal absorption of enalapril has been reported to involve peptide transporter 1 [12, 13].
Meanwhile, intestinal absorption of the highly hydrophobic VPP seems to occur via a paracellular pathway involving tight junctions, rather than involving a peptide transporter . Furthermore, the FMP effects disappeared when a lower concentration was employed, perhaps indicating a dose-dependent effect or involvement of a saturable transporter. In addition, intestinal peptide transporters (PEPT1 and PEPT2) exhibit high affinity for endogenous peptides but it was not the case occasionally. It may be probable that VPP exhibits very low affinity to be saturated in such concentration range. Therefore, further investigation is required to evaluate FMP pharmacokinetics and to elucidate the mechanism of the observed interaction with enalapril.
Long-term administration study
The present study found no significant differences in the antihypertensive effects of a single oral administration of enalapril monotherapy and oral enalapril followed by FMP 1 h later (data not shown). For this reason, we maintained a 1-h interval during dosing in the long-term study. As the result, compared to the control group, the enalapril monotherapy group showed significant antihypertensive effects on days 28, 35, 38, and 42 (p < 0.05 for all days, Fig. 2). Although administration of enalapril and FMP with an interval of 1 h between oral doses resulted in significant antihypertensive effects (p < 0.05 on day 35 for the comparison with control animals), a delayed onset was observed in comparison to that observed with enalapril monotherapy. Despite selecting this administration method, it became clear that long-term administration of enalapril and FMP produced a lower antihypertensive effect than did enalapril monotherapy. Although the mechanism underlying this effect is unknown, one possible explanation is an interaction at ACE catalytic sites in vivo. Although the precise mechanisms responsible for the in vivo antihypertensive effects of FMP, or the IPP/VPP tripeptides, have not been elucidated clearly, they have been suggested to involve ACE inhibition , or vasodilator production . IPP and VPP may also target the aorta, where they interact with ACE catalytic sites, inhibiting ACE activity [16–18].
When enalapril monotherapy was supplemented by FMP, significant antihypertensive effects were observed on days 35 and 42 (both p < 0.05) in the delayed combination group. Moreover, these effects were not significantly different from those observed during enalapril monotherapy (Fig. 2). This suggested that FMP administration had no effect on ongoing enalapril treatment. This may relate to the finding by many studies that FMP (or VPP/IPP) only exert their effects in subjects with clinically established hypertension [7, 19–23].
Many previous reports have shown that the long-term intake of FMP, or IPP and VPP tripeptides, effectively lowers blood pressure in SHR [10, 24] and humans [7, 8, 19–22, 25–27]. However, this is the first report of a potential interaction between an ACE inhibitor and a FOSHU product containing ACE inhibitory peptides in SHR with long-term administration.
The present findings suggested that long-term concomitant intake of FMP and enalapril could influence the antihypertensive effects of this drug. Therefore, they may be beneficial to people who have health concerns about taking ACE inhibitors over extended periods of time.
Arai S, Osawa T, Ohigashi H, Yoshikawa M, Kaminogawa S, Watanabe M, et al. A mainstay of functional food science in Japan-history, present status, and future outlook. Biosci Biotechnol Biochem. 2001;65:1–13.
Pripp AH. Effect of peptides derived from food proteins on blood pressure: a meta-analysis of randomized controlled trials. Food Nutr Res. 2008;52.
Xu JY, Qin LQ, Wang PY, Li W, Chang C. Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition. 2008;24:933–40.
Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25:425–36.
Nakamura Y, Yamamoto N, Sakai K, Takano T. Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci. 1995;78:1253–7.
Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazakim S, Takano T. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci. 1995;78:777–83.
Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr. 1996;64:767–71.
Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr. 2005;24:257–65.
Fujita H, Yoshikawa M. LKPNM: a prodrug-type ACE-inhibitory peptide derived from fish protein. Immunopharmacology. 1999;44:123–7.
Sipola M, Finckenberg P, Santisteban J, Korpela R, Vapaatalo H, Nurminen ML. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J Physiol Pharmacol. 2001;52:745–54.
Matsui T, Zhu XL, Watanabe K, Tanaka K, Kusano Y, Matsumoto K. Combined administration of captopril with an antihypertensive Val-Tyr di-peptide to spontaneously hypertensive rats attenuates the blood pressure lowering effect. Life Sci. 2006;79:2492–8.
Swaan PW, Stehouwer MC, Tukker JJ. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochim Biophys Acta. 1995;1236:31–8.
Knütter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008;327:432–41.
Satake M, Enjoh M, Nakamura Y, Takano T, Kawamura Y, Arai S, et al. Transepithelial transport of the bioactive tripeptide, Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci Biotechnol Biochem. 2002;66:378–84.
Hirota T, Nonaka A, Matsushita A, Uchida N, Ohki K, Asakura M, et al. Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels. 2001;26:549–56.
Masuda O, Nakamura Y, Takano T. Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr. 1996;126:3063–8.
Nakamura Y, Masuda O, Takano T. Decrease of tissue angiotensin I-converting enzyme activity upon feeding sour milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem. 1996;60:488–9.
Pina AS, Roque AC. Studies on molecular recognition between bioactive peptides and angiotensin-converting enzyme. J Mol Recognit. 2009;22:162–8.
Jauhiainen T, Vapaatalo H, Poussa T, Kyrönpalo S, Rasmussen M, Korpela R. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens. 2005;18:1600–5.
Mizushima S, Ohshige K, Watanabe J, Kimura M, Kadowaki T, Nakamura Y, et al. Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens. 2004;17:701–6.
Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr. 2003;77:326–30.
Tuomilehto J, Lindström J, Hyyrynen J, Korpela R, Karhunen M-L, Mikkola L, et al. Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens. 2004;18:795–802.
Engberink MF, Schouten EG, Kok FJ, van Mierlo LA, Brouwer IA, Geleijnse JM. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension. 2008;51:399–405.
Sipola M, Finckenberg P, Korpela R, Vapaatalo H, Nurminen ML. Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res. 2002;69:103–11.
Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, et al. Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr. 2005;94:84–91.
Sano J, Ohki K, Higuchi T, Aihara K, Mizuno S, Kajimoto O, et al. Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food. 2005;8:423–30.
Seppo L, Kerojoki O, Suomalainen T, Korpela R. The effect of Lactobacillus helveticus LBK-16 H fermented milk on hypertension - a pilot study on humans. Milchwissenschaft. 2002;57:124–7.
The authors declare that they have no competing interests.
Conceived and designed the experiments: MW, JK. Performed the experiments: SS. Analyzed the data: FI. Contributed reagents/materials/analysis tools: KN, HH. Wrote the paper: MW. All authors read and approved the final manuscript.
Rights and permissions
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Watanabe, M., Kurihara, J., Suzuki, S. et al. The influence of dietary peptide inhibitors of angiotensin-converting enzyme on the hypotensive effects of enalapril. J Pharm Health Care Sci 1, 17 (2015). https://doi.org/10.1186/s40780-015-0018-3
- Drug interaction
- Fermented milk
- Angiotensin I-converting enzyme inhibitor
- Concomitant administration
- Foods for specified health uses